natgillin/translations-raw huggingface dataset:
Do not turn the vial and syringe upside down, the vial should stay upright. 
Viale z brizgo ne obračajte na glavo, viala mora stati pokonci.
Appropriate screening tests (e.g. tuberculin skin test, interferon gamma release assay or chest X-ray) should be performed in all patients (local recommendations may apply). 
Pri vseh bolnikih je treba izvesti ustrezne presejalne teste (na primer tuberkulinski kožni test, gama interferonske teste ali rentgensko slikanje pljuč; v skladu z lokalnimi priporočili).
Accordingly, Tmax was shorter (3.6 days) in younger SJIA patients (2-3 years) compared to older SJIA patients (12-19 years; Tmax 6 days). 
V skladu s tem je pri mlajših bolnikih s SJIA (starih 2-3 leta) koncentracija hitreje dosegla najvišje vrednosti (Tmax je bil 3,6 dneva) kot pri starejših bolnikih s SJIA (starih 12-19 let, pri katerih je Tmax znašal 6 dni).
Overall, there were no clinically meaningful differences in the safety and tolerability profile of canakinumab in paediatric patients compared to the overall CAPS population (comprised of adult and paediatric patients, N=211), including the overall frequency and severity of infectious episodes. 
Klinično pomembnih razlik glede varnostnih lastnosti in učinkovitosti kanakinumaba pri pediatrični populaciji v primerjavi s celotno populacijo bolnikov s CAPS (ki jo sestavljajo odrasli in pediatrični bolniki, N=211) ni bilo, kar velja tudi za pogostnost vseh okužb in njihovo resnost.
Treatment with canakinumab resulted in a rapid and sustained improvement of both the articular and the systemic features of SJIA with significant reduction of the number of inflamed joints, prompt resolution of fever and reduction of acute phase reactants in the majority of patients (see Clinical efficacy and safety). 
Zdravljenje s kanakinumabom je omogočilo hitro in trajno izboljšanje tako sklepnih kot sistemskih znakov SJIA, in sicer se je pri večini bolnikov bistveno zmanjšalo število vnetih sklepov, prišlo je do hitrega znižanja zvišane telesne temperature in znižanja vrednosti beljakovin akutne faze (glejte Klinična učinkovitost in varnost).
Infections of the upper respiratory tract were the most frequently reported infection events. 
Od okužb so najbolj pogosto poročali o okužbah zgornjih dihal.
This is consistent with the observations of higher exposure in higher body weight groups in CAPS patients. 
Navedeno se ujema z ugotovitvijo, da je v skupinah bolnikov s CAPS z večjo telesno maso tudi izpostavljenost zdravilu večja.
Ilaris can be used alone or in combination with methotrexate. 
Zdravilo Ilaris je mogoče uporabljati samostojno ali v kombinaciji z metotreksatom.
Study G2306 was an open-label study to assess maintenance of treatment response with canakinumab dose reduction (2 mg/kg every 4 weeks) or dose interval prolongation (4 mg/kg every 8 weeks) in SJIA patients who were receiving canakinumab 4 mg/kg every 4 weeks. 
Študija G2306 je bila odprta študija za oceno ohranjanja odziva na zdravljenje ob znižanem odmerku kanakinumaba (2 mg/kg vsake 4 tedne) ali ob podaljšanem intervalu odmerjanja (4 mg/kg vsakih 8 tednov) pri bolnikih s SJIA, ki so prej prejemali kanakinumab v odmerku 4 mg/kg vsake 4 tedne.
Patients with Still's disease may develop a condition called macrophage activation syndrome (MAS), which can be life-threatening. 
Pri bolnikih s Stillovo boleznijo lahko pride do motnje, ki jo imenujemo sindrom aktivacije makrofagov in je lahko življenjsko nevarna.
The safety and efficacy of Ilaris in SJIA patients under 2 years of age have not been established. 
Varnost in učinkovitost zdravila Ilaris pri bolnikih, ki imajo SJIA in so stari manj kot 2 leti, nista bili dokazani.
Not included in the pack one vial (or ampoule) of sterile water for injections (“water”) (at room temperature) one 1.0 ml syringe one 18 G x 2 inch (50 mm) needle for reconstituting the powder (“transfer needle”) one 27 G x 0.5 inch (13 mm) needle for injecting (“injection needle”) alcohol swabs clean, dry cotton swabs an adhesive plaster a proper disposal container for used needles, syringe and vials (sharps container) 
Kar ni priloženo pakiranju eno vialo (ali ampulo), ki vsebuje sterilno vodo za injekcije ("vodo"), (sobne temperature) eno brizgo 1,0 ml eno iglo 18 G x 2 palca (50 mm) za rekonstituiranje praška ("iglo za prenos") eno iglo 27 G x 0,5 palca (13 mm) za injiciranje ("injekcijsko iglo") alkoholne blazinice čiste suhe bombažne zložence adhezivni obliž ustrezen zabojnik za uporabljene igle, brizge in viale (zbiralnik za ostre predmete)
Seventy five patients aged 2 to 22 years who maintained inactive disease status for at least 6 consecutive months (clinical remission) with canakinumab monotherapy, including patients who were able to maintain inactive disease status with discontinuation of concomitant corticosteroid and/or methotrexate use for at least 4 weeks, were randomised to receive canakinumab 2 mg/kg every 4 weeks (N=38) or canakinumab 4 mg/kg every 8 weeks (N=37). 
Petinsedemdeset bolnikov, ki so bili stari od 2 do 22 let in so ohranjali status neaktivne bolezni najmanj 6 zaporednih mesecev (klinično remisijo) ob prejemanju samo kanakinumaba, vključno z bolniki, ki so uspeli najmanj 4 tedne ohranjati status neaktivne bolezni kljub prekinitvi sočasne uporabe kortikosteroidov in/ali metotreksata, je bilo randomiziranih tako, da so prejemali bodisi kanakinumab 2 mg/kg vsake 4 tedne (N=38) ali kanakinumab 4 mg/kg vsakih 8 tednov (N=37).
Open the wrapper containing the injection needle and attach the needle to the syringe. 
Odprite zavoj z injekcijsko iglo in iglo namestite na brizgo.
This is administered every eight weeks as a single dose via subcutaneous injection. 
Bolniki vsakih osem tednov prejmejo en odmerek s subkutano injekcijo.
The rate of adverse events in both treatment arms was similar to the rate seen in patients treated with canakinumab 4 mg/kg every 4 weeks. 
Pogostnost neželenih dogodkov je bila v obeh zdravljenih skupinah podobna kot pri bolnikih, ki so prejemali kanakinumab v odmerku 4 mg/kg vsake 4 tedne.
Talk to your doctor before using Ilaris if any of the following applies to you: if you currently have an infection or if you have had repeated infections or a condition such as a known low level of white blood cells which makes you more likely to get infections. 
Pred začetkom uporabe zdravila Ilaris se posvetujte z zdravnikom, če za vas velja karkoli od spodaj navedenega: če imate trenutno katero od okužb ali če so se vam kdaj ponavljale okužbe ali stanja, kot je ugotovljeno znižano število levkocitov, zaradi česar je možnost za razvoj okužbe pri vas večja; če imate ali ste imeli kdaj prej tuberkulozo ali ste prišli v neposreden stik z osebo z aktivno tuberkulozo.
Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate (see section 5.1). 
Zdravilo Ilaris je indicirano za simptomatsko zdravljenje odraslih bolnikov s pogostimi napadi uričnega artritisa (z najmanj 3 napadi v predhodnih 12 mesecih), pri katerih je uporaba nesteroidnih protivnetnih zdravil in kolhicina kontraindicirana, jih bolnik ne prenaša ali ne povzročajo zadostnega odziva, in pri katerih ponavljajoči se ciklusi zdravljenja s kortikosteroidi niso primerni (glejte poglavje 5.1).
Hepatic function 
Jetrna funkcija
The other was an open-label study with canakinumab to evaluate the efficacy and safety in Japanese CAPS patients for 24 weeks, with an extension phase up to 48 weeks. 
Druga študija je bila odprta, v njej pa so ocenjevali učinkovitost in varnost uporabe kanakinumaba pri japonskih bolnikih s CAPS najprej 24 tednov, nato pa še v podaljšanju študije do skupaj 48 tednov.
Hold the syringe at a 90-degree angle and in a single, smooth motion, push the needle straight down completely into the skin. 
Brizgo držite pod kotom 90 stopinj in jo z enim samim enakomernim gibom potisnite navzdol, tako da bo cela igla v kožni gubi.
The second patient received a starting dose of canakinumab 2 mg/kg and an add-on dose of 2 mg/kg at week 3, and was up-titrated at week 5 to receive a dose of 4 mg/kg administered every 4 weeks until the end of Part II of the study. 
Drugi bolnik je prejel začetni odmerek kanakinumaba 2 mg/kg, po 3 tednih je prejel dodatni odmerek 2 mg/kg, po koncu 5. tedna pa so mu zvišali odmerek na 4 mg/kg vsake 4 tedne, kar je prejemal do konca 2. obdobja v študiji.
Patients must be monitored closely for signs and symptoms of tuberculosis during and after treatment with canakinumab. 
Bolnike je treba med zdravljenjem s kanakinumabom in po njem natačno spremljati glede znakov in simptomov tuberkuloze.
Injecting Ilaris yourself or injecting a patient with Ilaris If you are a patient with CAPS, TRAPS, HIDS/MKD, FMF or Still's disease (AOSD or SJIA), or a caregiver of a patient with one of these conditions, you may administer Ilaris injections yourself after proper training in the correct injection technique. 
Samoinjiciranje zdravila Ilaris ali injiciranje zdravila Ilaris bolniku Če ste bolnik s katerim od sindromov CAPS, TRAPS, HIDS/MKD ali FMF ali s Stillovo boleznijo (AOSD ali SJIA) ali če ste skrbnik bolnika s katero od navedenih bolezni, lahko sami injicirate zdravilo Ilaris, če ste se ustrezno izurili v pravilni tehniki injiciranja.
In study G2305, the Childhood Health Assessment Questionnaire Least Squares means improvement was 0.69 for canakinumab vs placebo representing 3.6 times the minimal clinically important difference of 0.19 (p=0.0002). 
V študiji G2305 so bili rezultati Vprašalnika za oceno zdravja v otroštvu (Childhood Health Assessment Questionnaire) po metodi najmanjših kvadratov pri uporabi kanakinumaba za 0,69 točke boljši kot pri uporabi placeba, kar predstavlja 3,6-kratnik minimalne klinično pomembne spremembe 0,19 (p=0,0002).
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). 
Periodični sindrom povezan z receptorjem za tumor nekrotizirajoči factor (TNF) (TRAPS-tumour necrosis factor receptor associated periodic syndrome) Zdravilo Ilaris je indicirano za zdravljenje periodičnega sindroma, ki je povezan z receptorjem za TNF (TRAPS).
Study G2305 
Študija G2305
Using aseptic technique, reconstitute each vial of canakinumab at room temperature (typically 15°C to 25°C) by slowly injecting 1 ml water for injections with a 1 ml syringe and an 18 G x 2 inch (50 mm) needle. 
Kanakinumab v viali z aseptično tehniko rekonstituirajte pri sobni temperaturi (običajno pri 15°C do 25°C), in sicer tako, da v vialo počasi injicirate 1 ml vode za injekcije z 1-mililitrsko injekcijsko brizgo in iglo 18 G x 2 palca (50 mm).
Slowly pull the syringe plunger up to the correct mark (amount to be given as per healthcare provider's instructions), filling the syringe with Ilaris solution. 
Počasi potegnite bat brizge navzgor do pravilne oznake (do oznake za količino, ki jo morate odmeriti po navodilu usposobljenega zdravstvenega delavca) in tako napolnite brizgo z raztopino Ilaris.
Clean the rubber stopper of the vial containing the Ilaris solution with a new alcohol swab. 
Gumijast zamašek na viali, ki vsebuje zdravilo Ilaris, očistite z novo alkoholno blazinico.
It blocks the activity of a substance called interleukin-1 beta (IL-1 beta) in the body, which is present at increased levels in inflammatory diseases. 
Zavira delovanje snovi, ki jo imenujemo interlevkin-1 beta (IL-1 beta) in jo najdemo v telesu, pri vnetnih boleznih pa je njena koncentracija zvišana.
These include shivering, chills, malaise, loss of appetite, body aches, typically in connection with a sudden onset of illness, sore throat or mouth ulcers, cough, phlegm, chest pain, difficulty breathing, ear pain, prolonged headache or localised redness, warmth or swelling of your skin or inflammation of connective tissue (cellulitis). 
Ti simptomi vključujejo drgetanje, mrzlico, splošno slabo počutje, izgubo apetita, bolečine po telesu, ki so navadno povezane z nenadnim nastopom bolezni, vneto grlo oziroma žrelo ali razjede v ustih, kašelj, izkašljevanje sluzi, bolečine v prsih, oteženo dihanje, bolečine v ušesu, dolgotrajen glavobol ali rdečino, toploto ali oteklino na omejenem predelu kože ali vnetje vezivnega tkiva (flegmona).
Experience from individual patients who achieved a complete response following dose escalation to 600 mg (8 mg/kg) every 8 weeks suggests that a higher dose may be beneficial in patients not achieving complete response or not maintaining complete response with the recommended doses (150 mg or 2 mg/kg for patients ≥ 15 kg and ≤ 40 kg). 
Izkušnje pri posameznih bolnikih, pri katerih je prišlo do popolnega odziva po zvišanju odmerka na 600 mg (8 mg/kg) vsakih 8 tednov, kažejo, da višji odmerki lahko koristijo bolnikom, pri katerih pri uporabi priporočenih odmerkov (150 mg oziroma 2 mg/kg za bolnike s telesno maso ≥ 15 kg in ≤ 40 kg) ni prišlo do popolnega odziva ali pa se ta ni ohranil.
Part III: Patients treated with placebo in Part II who flared regained and maintained clinical and serological response following entry into the open-label canakinumab extension. 
3. obdobje: Pri bolnikih, ki so v 2. obdobju prejemali placebo in pri katerih je prišlo do zagona bolezni, je po vključitvi v podaljšanje z odprtim zdravljenjem s kanakinumabom ponovno prišlo do kliničnega in serološkega odziva, ki se je tudi ohranil.
Although limited, evidence from the clinical trials suggests that patients not responding to tocilizumab or anakinra may respond to canakinumab. 
Podatki iz kliničnih študij, čeprav omejenega obsega, kažejo, da pri bolnikih, ki se ne odzivajo na zdravljenje s tocilizumabom oziroma anakinro, lahko pride do odziva na zdravljenje s kanakinumabom.
Animal studies indicate that canakinumab crosses the placenta and is detectable in the foetus. 
Rezultati študij na živalih kažejo, da kanakinumab prehaja preko placente in pri plodu doseže merljivo koncentracijo.
• Neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurological, cutaneous, articular syndrome (CINCA), 
• multisistemska vnetna bolezen z začetkom pri novorojenčku (angleško neonatal-onset multisystem inflammatory disease - NOMID), ki se imenuje tudi kronični vnetni nevrološki, kožni in sklepni sindrom pri dojenčku (angleško chronic infantile neurological, cutaneous, articular syndrome - CINCA),
Ensure that the correct amount of solution is in the syringe. 
Preverite, če je v brizgi res ustrezna količina raztopine.
In this study, 25 patients who had a strong ACR response for a minimum of 5 months reduced their canakinumab dose to 2 mg/kg every 4 weeks and maintained a paediatric ACR100 response throughout the time the reduced dose was given (median 32 weeks, 8-124 weeks). 
V tem podaljšanju je 25 bolnikov z močnim odzivom po kriterijih ACR za najmanj 5 mesecev znižalo odmerjanje kanakinumaba na 2 mg/kg vsake 4 tedne in ves čas prejemanja znižanih odmerkov ohranilo odziv po pediatričnih kriterijih ACR100 (mediano 32 tednov, od 8 do 124 tednov).
The safety and efficacy of Ilaris in CAPS, TRAPS, HIDS/MKD and FMF patients under 2 years of age have not been established. 
Varnost in učinkovitost zdravila Ilaris pri bolnikih, ki imajo CAPS ali katerega od sindromov TRAPS, HIDS/MKD ali FMF in so stari manj kot 2 leti, nista bili dokazani.
Study G2305 was a randomised, double-blind, placebo-controlled, 4-week study assessing the shortterm efficacy of canakinumab in 84 patients randomised to receive a single dose of 4 mg/kg (up to 300 mg) canakinumab or placebo. 
Študija G2305 je bila randomizirana, dvojno slepa, s placebom kontrolirana 4-tedenska študija, v kateri so ocenjevali kratkoročno učinkovitost kanakinumaba pri 84 bolnikih, ki so jih randomizirali tako, da so prejeli enkraten odmerek 4 mg/kg (največ 300 mg) kanakinumaba ali placebo.
Canakinumab also demonstrated superior efficacy compared to placebo on the secondary endpoints of PGA < 2 and CRP ≤ 10 mg/l in all three cohorts. 
Kanakinumab je bil v vseh treh kohortah bolj učinkovit od placeba tudi pri sekundarnih ciljih študije: pri doseganju ocene < 2 na lestvici PGA in vrednosti CRP ≤ 10 mg/l.
Antibodies against Ilaris were observed in approximately 1.5%, 3% and 2% of the patients treated with Ilaris for CAPS, SJIA and gouty arthritis, respectively. 
Protitelesa proti zdravilu Ilaris so opažali pri približno 1,5 % bolnikov, ki so prejemali zdravilo Ilaris zaradi CAPS, pri 3 % bolnikov, ki so prejemali zdravilo zaradi SJIA, in pri 2 % bolnikov, ki so prejemali zdravilo zaradi uričnega artritisa.
In active-controlled gouty arthritis trials, there was a mean increase in triglycerides of 33.5 mg/dl in canakinumab-treated patients compared with a modest decrease of -3.1 mg/dl with triamcinolone acetonide. 
V aktivno kontroliranih preskušanjih pri bolnikih z uričnim artritisom je pri bolnikih, ki so prejemali kanakinumab, prišlo do povprečnega zvišanja vrednosti trigliceridov za 33,5 mg/dl v primerjavi z zmernim znižanjem za -3,1 mg/dl pri bolnikih, ki so prejemali triamcinolon acetonid.
If you forget to use Ilaris 
Če ste pozabili uporabiti zdravilo Ilaris
Live vaccines: You are advised to avoid being vaccinated with a type of vaccine called a live vaccine while you are being treated with Ilaris. 
Živa cepiva: Priporočeno je, da se v času zdravljenja z zdravilom Ilaris izogibate cepljenju z vrsto cepiv, ki jih imenujemo "živa cepiva".
In a subset of young adult SJIA patients aged 16 to 20 years (n=31), the safety profile of canakinumab was consistent with what was observed in SJIA patients less than 16 years of age. 
V podskupini mladih odraslih bolnikov s SJIA, ki so bili stari od 16 do 20 let (n=31), je bil varnostni profil kanakinumaba podoben kot pri tistih bolnikih s SJIA, ki so bili stari manj kot 16 let.
The efficacy and safety of canakinumab have been demonstrated in a total of 211 adult and paediatric patients with varying degrees of disease severity and different CAPS phenotypes (including FCAS/FCU, MWS, and NOMID/CINCA). 
S kriopirinom povezani periodični sindromi (CAPS) Varnost in učinkovitost kanakinumaba so dokazali pri skupno 211 odraslih in pediatričnih bolnikih z različnimi stopnjami izraženosti in z različnimi fenotipskimi oblikami bolezni s kriopirinom povezanih periodičnih sindromov (CAPS), vključno s sindromi FCAS/FCU, MWS in NOMID/CINCA.
Efficacy results in a subgroup of patients unable to use both NSAIDs and colchicine and who were on ULT, failed ULT or had a contraindication to ULT (N=101) were consistent with the overall study population with a statistically significant difference compared to triamcinolone acetonide in pain intensity at 72 hours (-10.2 mm, p=0.0208) and in reduction of risk of subsequent attacks (Hazard ratio 0.39, p=0.0047 at 24 weeks). 
V skupini bolnikov, ki niso mogli uporabljati niti nesteroidnih protivnetnih zdravil niti kolhicina in so uporabljali zdravila, ki znižujejo količino urata, ali pa je bilo pri njih zdravljenje z njimi neuspešno ali kontraindicirano (N=101), so bili rezultati glede učinkovitosti skladni z rezultati celotne študijske populacije s statistično značilno razliko v primerjavi z uporabo triamcinolon acetonida, in sicer glede intenzivnosti bolečine po 72 urah (-10,2 mm, p=0,0208) in glede tveganja za nadaljnje napade (razmerje ogroženosti (HR) 0,39, p=0,0047 po 24 tednih).
TRAPS n=number of responders; N=number of evaluable patients * indicates statistical significance (one-sided) at the 0.025 level based on Fisher exact test **Indicates statistical significance (one-sided) at the 0.025 level based on the logistic regression model with treatment group and baseline PGA, CRP or SAA respectively, as explanatory variables for each cohort 
TRAPS n=število bolnikov z odzivom; N=število bolnikov, ki so bili primerni za vrednotenje * pomeni statistično značilnost (enosmerno) za raven verjetnosti 0,025 na osnovi Fisherejevega eksaktnega testa ** pomeni statistično značilnost (enosmerno) za raven verjetnosti 0,025 na osnovi modela logistične regresije, v katerem so način zdravljenja in izhodiščne vrednosti ocene PGA, CRP ter SAA pojasnjevalne spremenljivke v posamezni kohorti
Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks. 
Iz tega razloga v času zdravljenja s kanakinumabom bolniki ne smejo biti cepljeni z živimi cepivi, razen če koristi nedvomno odtehtajo tveganja.
This is administered every four weeks as a single dose via subcutaneous injection. 
Bolniki vsake štiri tedne prejmejo en odmerek s subkutano injekcijo.
If you stop using Ilaris 
Če ste prenehali uporabljati zdravilo Ilaris
Ilaris is used in adults, adolescents and children to treat active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older if other treatments have not worked well enough. 
Zdravilo Ilaris uporabljamo pri odraslih, mladostnikih in otrocih za zdravljenje aktivne Stillove bolezni, ki vključuje Stillovo bolezen z začetkom v odrasli dobi (AOSD) in sistemski juvenilni idiopatski artritis (SJIA), pri bolnikih, ki so stari 2 leti ali več, če druga zdravila pri njih niso dovolj dobro delovala.
- Do not use this medicine after the expiry date which is stated on the label and carton. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli.
Maintenance dose: 150 mg every 4 weeks 
Vzdrževalni odmerek: 150 mg vsake 4 tedne
In the pooled efficacy analysis for these two studies, 65.6% of patients who had not previously been treated with canakinumab achieved complete response at 150 mg or 2 mg/kg, while 85.2% of patients achieved complete response at any dose. 
Rezultati analize podatkov o učinkovitosti iz obeh navedenih študij, kažejo, da je pri odmerjanju 150 mg oziroma 2 mg/kg prišlo do popolnega odziva pri 65,6 % bolnikov, ki predhodno niso bili zdravljeni s kanakinumabom, pri kateremkoli odmerku pa je do popolnega odziva prišlo pri 85,2 % bolnikov.
If not used immediately, the solution should be stored in the refrigerator (2°C - 8°C) and used within 24 hours. 
Če raztopine ne uporabite takoj, jo morate hraniti v hladilniku (pri temperaturi 2 °C do 8 °C) in uporabiti v roku 24 ur.
Ilaris blocks the activity of IL-1 beta, which may improve the signs and symptoms of Still's disease. 
Zdravilo Ilaris zavira delovanje IL-1-beta, kar lahko izboljša znake in simptome Stillove bolezni.
Do not use Ilaris - if you are allergic to canakinumab or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Ilaris - če ste alergični na kanakinumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če imate ali domnevate, da imate hudo okužbo, ki je aktivna.
Gouty arthritis There is no relevant use of Ilaris in the paediatric population in the indication gouty arthritis. 
Zdravilo Ilaris ni primerno za uporabo pri pediatrični populaciji za indikacijo uričnega artritisa.
For instructions on how to administer Ilaris injections, please read the section “Instructions for use” at the end of this leaflet. 
Navodila glede injiciranja zdravila Ilaris lahko preberete v poglavju "Navodila za uporabo praška za raztopino za injiciranje zdravila Ilaris" na koncu teh navodil.
150 mg or 2 mg/kg 
150 mg oziroma 2 mg/kg
Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). 
Družinska mediteranska vročica (FMF-familial Mediterranean fever) Zdravilo Ilaris je indicirano za zdravljenje družinske mediteranske vročice (FMF).
An additional pharmacokinetics analysis showed that the pharmacokinetics of canakinumab in 6 paediatric CAPS patients under the age of 2 years were similar to the pharmacokinetics in paediatric patients 2-4 years of age. 
Dodatna farmakokinetična analiza je pokazala, da je bila farmakokinetika kanakinumaba pri 6 pediatričnih bolnikih s CAPS, ki so bili stari manj kot 2 leti, podobna farmakokinetiki pri pediatričnih bolnikih, ki so bili stari od 2 do 4 leta.